Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria.

Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV.

J Infect Dis. 2002 Feb 1;185(3):380-8.

2.
3.

Antifolates can have a role in the treatment of Plasmodium vivax.

Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH.

Trends Parasitol. 2007 May;23(5):213-22. Review.

PMID:
17368986
4.

Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?

Nzila A, Ochong E, Nduati E, Gilbert K, Winstanley P, Ward S, Marsh K.

Trans R Soc Trop Med Hyg. 2005 May;99(5):341-6. Review.

PMID:
15780340
5.

Drug resistance maps to guide intermittent preventive treatment of malaria in African infants.

Naidoo I, Roper C.

Parasitology. 2011 Oct;138(12):1469-79. doi: 10.1017/S0031182011000746. Review.

6.

Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes.

Brabin BJ, Eggelte TA, Parise M, Verhoeff F.

Drug Saf. 2004;27(9):633-48. Review.

PMID:
15230645
7.

Malaria 1984. Part I. Malaria prophylaxis.

Spracklen FH.

S Afr Med J. 1984 Jun 30;65(26):1037-41. Review.

PMID:
6377524
Items per page

Supplemental Content

Support Center